Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta …
P Hu, KI Dharmayat, CAT Stevens, MTA Sharabiani… - Circulation, 2020 - Am Heart Assoc
Background: Contemporary studies suggest that familial hypercholesterolemia (FH) is more
frequent than previously reported and increasingly recognized as affecting individuals of all …
frequent than previously reported and increasingly recognized as affecting individuals of all …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus …
HN Ginsberg, CJ Packard, MJ Chapman… - European heart …, 2021 - academic.oup.com
Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …
preclinical, and clinical trial results, provide strong support for a causal association between …
[HTML][HTML] Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database
S Nguengang Wakap, DM Lambert, A Olry… - European Journal of …, 2020 - nature.com
Rare diseases, an emerging global public health priority, require an evidence-based
estimate of the global point prevalence to inform public policy. We used the publicly …
estimate of the global point prevalence to inform public policy. We used the publicly …
[HTML][HTML] Inclisiran for the treatment of heterozygous familial hypercholesterolemia
Background Familial hypercholesterolemia is characterized by an elevated level of low-
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …
density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic …
[HTML][HTML] Evinacumab for homozygous familial hypercholesterolemia
Background Homozygous familial hypercholesterolemia is characterized by premature
cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) …
cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) …
2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance
This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
TR Tromp, ML Hartgers, GK Hovingh, AJ Vallejo-Vaz… - The Lancet, 2022 - thelancet.com
Summary Background Homozygous familial hypercholesterolaemia (HoFH) is a rare
inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels …
inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels …
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the …
BA Ference, HN Ginsberg, I Graham… - European heart …, 2017 - academic.oup.com
Aims To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs)
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
cause atherosclerotic cardiovascular disease (ASCVD). Methods and results We assessed …
GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy
LN Kasiewicz, S Biswas, A Beach, H Ren… - Nature …, 2023 - nature.com
Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic
modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated …
modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated …